| Page 41 | Cafepharma

You are here

Primary tabs

Cidara Therapeutics Initiates Ph III Trial of Rezafungin for Treatment of Invasive Candida Infections

Post date: September 27, 2018 - 10:23am

CytoSen Therapeutics Receives Favorable Response to Pre-IND Meeting Package for Phase 2 Study in Acute Myeloid Leukemia

Post date: September 27, 2018 - 9:57am

Veracyte to Present Data Supporting Use of Their Non-Invasive Diagnostics for Lung Diseases

Post date: September 27, 2018 - 9:36am

ENT Focused Lyra Therapeutics Banks $29.5 Million Series B Round

Post date: September 26, 2018 - 9:49am

AI Digital Pathology Company Closes $8.3 Million Series A Round

Post date: September 26, 2018 - 9:29am

Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug

Post date: September 25, 2018 - 10:12am

Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer

Post date: September 25, 2018 - 9:51am

Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer

Post date: September 25, 2018 - 9:33am

Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Huge Oral Mucositis Market

Post date: September 24, 2018 - 10:13am

Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

Post date: September 24, 2018 - 9:36am

Pages